DEA Schedule III Registration Window Closes June 22, 2026; Hearing Begins June 29

The most consequential change to United States federal marijuana law in more than fifty years is now moving on a fixed clock, and two dates in June 2026 matter more than any others. State-licensed medical marijuana operators have a roughly 60-day window to file for federal Drug Enforcement Administration (DEA) registration and preserve their right to keep operating while the agency reviews their applications. The conservative reading of that window closes on June 22, 2026. Days later, on June 29, 2026, the DEA opens an expedited administrative hearing that will decide whether the rest of cannabis, including adult-use product, should follow medical marijuana into Schedule III.

For United States operators, this is a hard compliance deadline with real consequences for missing it. For Canadian licensed producers (LPs) watching the American market, it is a signal: the United States is rebuilding its medical cannabis market around DEA-registered, federally controlled facilities, and the quality systems Canadian LPs already maintain under Health Canada and EU-GMP are about to become a competitive asset rather than a cost centre. This article explains what changed, what the June dates mean, who is covered, and what disciplined operators on both sides of the border should do now.

Executive summary

The order was issued under the Attorney General's treaty authority in 21 U.S.C. 811(d), which allows scheduling actions that carry out United States obligations under the 1961 Single Convention on Narcotic Drugs to take effect immediately, without notice-and-comment rulemaking. It followed President Trump's December 18, 2025 Executive Order 14370, Increasing Medical Marijuana and Cannabidiol Research, which directed the Department of Justice (DOJ) to complete rescheduling in the most expeditious manner permitted by law.

Two things did not change. Adult-use (recreational) marijuana, bulk marijuana, and synthetic THC remain in Schedule I. And interstate commerce in cannabis remains prohibited outside DEA-registered channels, so this order does not open the United States border to imports. Both points matter for Canadian LPs, and we return to them below.

Key dates at a glance

What the April 2026 order actually did

What is it? The order created a two-tier federal framework for marijuana for the first time. Rather than rescheduling all cannabis at once, the DOJ moved only two categories into Schedule III and left everything else in Schedule I.

Why does it matter? Schedule I substances cannot be lawfully manufactured, distributed, or sold under federal law in any form, and scientific research on them is tightly restricted. Schedule III substances can be manufactured, distributed, and dispensed by entities that hold a valid DEA registration and meet the Controlled Substances Act requirements for registration, fees, security, recordkeeping, inventory, reporting, disposal, and labelling. Moving medical marijuana to Schedule III therefore brings it inside the federally regulated pharmaceutical-style system for the first time.

What is covered, and what is not

A qualifying state medical licence is a state-issued licence authorizing the manufacture, distribution, or dispensing of marijuana for medical purposes. Operators that hold only an adult-use licence are not covered and remain Schedule I operators under federal law. The order also amended DEA regulations to require import and export permits for Schedule III marijuana products, mirroring the existing requirement for Schedule I and II substances and consistent with Article 31 of the Single Convention.

The June 22 deadline: why operators should not wait for June 27

What should companies do? File the DEA registration application now and treat June 22, 2026 as the deadline rather than gambling on a later date. Here is the nuance that has confused parts of the market, explained plainly.

The order created an expedited registration pathway. Applications submitted within 60 days of the order's publication in the Federal Register allow the operator to continue handling Schedule III marijuana compliantly during the review period, and the DEA is directed to process applications within six months. A valid state medical licence serves as conclusive evidence of state authorization.

The Federal Register publication date was April 28, 2026, so counting 60 days lands on or about June 27, 2026. However, the hearing notice published the same day fixes June 22, 2026 as the date the Acting Attorney General will notify selected hearing participants and designate the Administrative Law Judge. Some practitioners count the 60 days from the April 23 announcement, which also lands on June 22. Because the earlier date is defensible and the cost of missing the safe harbor is severe, the disciplined approach is to file on or before June 22, 2026.

Registration is effectively mandatory. Handling a Schedule III controlled substance without a DEA registration is a federal violation. Manufacturers, distributors, and dispensers each register in their own category, and DEA registration fees apply per the current DEA Diversion Control fee schedule (for example, the published annual manufacturer registration fee). Operators should confirm the current fee and category at the time of filing rather than relying on a figure quoted in any secondary source.

The June 29 hearing: what is at stake for the rest of cannabis

The April order was explicitly framed as a first step. On the same day, the DOJ announced a new administrative hearing, beginning June 29, 2026 at 9 a.m. ET at the DEA Hearing Facility in Arlington, Virginia, to consider whether all forms of marijuana, including adult-use, should be transferred from Schedule I to Schedule III through formal rulemaking. The hearing will conclude no later than July 15, 2026, with a recess from July 3 to July 6 for the 250th anniversary of American Independence.

This proceeding replaces an earlier process. A proposed rule was published in May 2024 and a hearing was scheduled for December 2024, but those proceedings were stayed in January 2025 and the DEA's sole Administrative Law Judge retired in July 2025. The DEA has now withdrawn the prior notice of hearing, terminated the earlier proceedings, and replaced them with new proceedings under firm deadlines. The written notice period to participate has already closed, so the practical question for most operators is not whether to participate but how to prepare for the likely outcomes.

How does it affect compliance? A favourable outcome could extend Schedule III status to all marijuana, but that is not guaranteed, and a final rule could take months after the hearing concludes. Until any broader rule is final, adult-use activity remains Schedule I with all of the associated federal exposure. Operators should plan for a range of outcomes rather than assuming the hearing resolves the question in their favour.

The dual-licence problem most operators underestimate

The most immediate and underappreciated risk falls on operators that hold both a medical and an adult-use licence in the same state, a common structure. These businesses are now subject to two different federal regimes at once. Medical activities are Schedule III, subject to DEA registration and Schedule III controls. Adult-use activities remain Schedule I, subject to full enforcement and the Section 280E tax disallowance.

Regulators may scrutinize whether inventory, staff, facilities, and financial flows are adequately separated between the two streams. Commingling, even inadvertently, could jeopardize Schedule III status for the medical side or expose the whole operation to Schedule I liability. Dual-licence operators should treat operational separation as an urgent priority: audit every point of overlap, implement physical, financial, and recordkeeping separation, and document the boundary clearly.

What this means for Canadian licensed producers

Does the order open the United States border to Canadian cannabis? No. Interstate and international commerce in marijuana remains prohibited outside DEA-registered channels, and the order added import and export permit requirements rather than removing barriers. Congressional action would still be required to permit cross-border commercial trade. Canadian LPs should not read this order as an export opening.

So why should Canadian LPs care? Because the direction of travel is unmistakable. The United States is reorganizing its medical cannabis market around DEA-registered facilities that must meet pharmaceutical-style controls for security, recordkeeping, inventory, reporting, and quality. That is precisely the discipline Canadian LPs already operate under through Health Canada licensing, Good Production Practices, and, for export-oriented producers, EU-GMP. As the United States market matures, the operators, investors, and partners who win will be the ones whose quality systems are inspection-ready and defensible on paper.

There are three practical implications for Canadian LPs. First, investment and partnership interest in United States medical assets will increasingly favour operators with mature quality management systems, because a DEA-registered facility lives or dies on documentation. Second, Canadian LPs evaluating eventual United States entry should build to a federally controlled standard now, so that a future pathway does not require rebuilding the quality system under deadline pressure. Third, the EU-GMP versus Good Production Practices decision becomes more strategic, because a single high-bar quality system can support Canadian compliance, European export, and credibility with United States partners at the same time. Our analysis of EU-GMP versus GPP sets out that trade-off in detail.

Compliance checklist: what disciplined operators should do now

For United States state-licensed medical operators:

• File the DEA registration application on or before June 22, 2026, supported by a valid state medical licence, to preserve the right to operate during review.
• Confirm the correct registration category (manufacturer, distributor, or dispenser) and the current fee on the DEA Diversion Control fee schedule before submitting.
• Assess whether current state-level security, labelling, disposal, inventory, and recordkeeping practices satisfy federal Schedule III requirements, and close any gaps.
• If you hold both medical and adult-use licences, separate the two operations physically, financially, and in your records, and document the separation.
• Consult tax counsel about Section 280E relief going forward and protective IRS refund claims for prior years, noting the limited refund window.
• Confirm import and export permit requirements before moving any Schedule III marijuana product across a border.

For Canadian LPs positioning for the United States and global markets:

• Map your existing Health Canada and Good Production Practices quality system against pharmaceutical-grade expectations for security, documentation, and traceability.
• Decide deliberately between Good Production Practices and EU-GMP based on your export and partnership strategy, not by default.
• Treat your quality management system documentation as diligence-ready, because investors and partners will read it as a proxy for operational control.
• Build CAPA, recall, and investigation processes that would withstand a federal-style inspection, regardless of jurisdiction.

Common mistakes to avoid

1. Assuming all cannabis is now Schedule III. Only FDA-approved products and qualifying state medical marijuana moved. Adult-use, bulk, and synthetic THC remain Schedule I.
2. Treating the deadline as soft. Waiting for June 27 instead of filing by June 22 risks the operating safe harbor on a date that is genuinely contested.
3. Commingling medical and adult-use operations. Dual-licence operators that fail to separate the two streams put their Schedule III status at risk.
4. Ignoring the new import and export permit requirement for Schedule III marijuana products.
5. Assuming state-law compliance automatically equals federal Schedule III compliance. The two overlap but are not identical, and the gaps are where inspections find problems.
6. For Canadian LPs, assuming the order opens the United States border. It does not. Cross-border commercial trade still requires Congressional action.

Frequently asked questions

What is the DEA Schedule III registration deadline?

State-licensed medical marijuana operators should file their DEA registration application within 60 days of the order's Federal Register publication on April 28, 2026. The conservative working deadline is June 22, 2026; the latest reading is on or about June 27, 2026. Filing within the window preserves the right to operate while the DEA reviews the application.

Does Schedule III make marijuana federally legal?

No. Schedule III status means medical marijuana can be lawfully handled by entities that hold a valid DEA registration and meet Controlled Substances Act requirements. It is regulated, not deregulated, and adult-use marijuana remains in Schedule I.

Are adult-use (recreational) operators covered?

No. The April 2026 order covers only FDA-approved marijuana products and marijuana under a qualifying state medical licence. Adult-use operators remain Schedule I and continue to face federal enforcement exposure and the Section 280E tax disallowance.

What happens if a state-licensed operator misses the registration window?

Missing the expedited window means entering the standard queue without the guaranteed ability to continue operating during review, and handling Schedule III marijuana without a registration is a federal violation. The practical risk is a gap in lawful operating authority.

What is the June 29, 2026 hearing about?

It is an expedited administrative hearing on whether all forms of marijuana, including adult-use, should be rescheduled from Schedule I to Schedule III through formal rulemaking. It runs from June 29 to no later than July 15, 2026, in Arlington, Virginia.

How does this affect Canadian licensed producers?

The order does not open the United States border, but it reorganizes the United States medical market around federally controlled, DEA-registered facilities. Canadian LPs with mature Health Canada and EU-GMP quality systems are well positioned for investment, partnership, and eventual market access, because federal regulators reward documented control.

Can Canadian LPs now export medical cannabis to the United States?

No. Interstate and international commerce in marijuana remains prohibited outside DEA-registered channels, and the order added import and export permit requirements. Cross-border commercial trade would require Congressional action.

What is Section 280E relief?

Section 280E of the Internal Revenue Code disallows business deductions for trafficking in Schedule I or II substances. Because medical marijuana is now Schedule III, state-licensed medical operators are no longer subject to that disallowance going forward, and may consider protective refund claims for prior years with tax counsel.

How MFLRC can help

MF License & Regulatory Consultants (MFLRC) helps cannabis operators and licensed producers build the quality systems and documentation that federal regulators reward. Whether you are a United States operator preparing for DEA-registered Schedule III operations or a Canadian LP positioning for global market access, the work is the same discipline: defensible, inspection-ready quality and compliance systems.

Our services across the regulatory lifecycle include:

• Gap assessments that map your current state against Schedule III, Good Production Practices, GMP, and EU-GMP expectations, through our quality assurance and compliance support.
• SOP development and quality management system builds, including the recordkeeping, inventory, security, and disposal controls that DEA-registered and Health Canada-licensed facilities must demonstrate.
• Licensing and post-licensing support, including Health Canada correspondence, import and export permits, recalls, investigations, and root cause analysis, through our post-licensing support team.
• Audit readiness and mock inspections, drawing on practical guidance such as our tips for passing a cannabis regulatory audit and the cannabis QA compliance checklist.
• Quality Assurance Person (QAP) services, CAPA program design, and validation and qualification support.
• Strategic standard selection, including the EU-GMP versus GPP decision and provincial licensing guidance such as our overview of provincial cannabis licences across Canada.

To understand how senior-led, practical regulatory consulting can de-risk your next move, learn more about MFLRC or see how cannabis licensing consultants streamline compliance.

Conclusion

June 2026 marks the moment United States medical cannabis enters the federally regulated system, and the deadlines are real. State-licensed medical operators should file their DEA registration on or before June 22, 2026, separate any dual-licence operations, and treat their quality systems as the foundation of lawful operation rather than an afterthought. The June 29 hearing will shape what comes next for adult-use cannabis, but it will not resolve the immediate obligations now in front of every medical operator.

For Canadian LPs, the message is strategic. The border has not opened, but the standard has been set. The operators who thrive in the next chapter of North American cannabis will be those whose documentation, controls, and quality systems can withstand federal scrutiny. That is work that can begin today, and it is exactly the work MFLRC was built to do.

Sources and references

• U.S. Department of Justice, Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III, April 23, 2026.
• Drug Enforcement Administration, DOJ, Schedules of Controlled Substances: Rescheduling of Marijuana, Notice of hearing on proposed rulemaking, 91 FR 22777, April 28, 2026 (Docket No. DEA-1362).
• The White House, Executive Order 14370, Increasing Medical Marijuana and Cannabidiol Research, December 18, 2025.
• Controlled Substances Act scheduling and treaty authority, 21 U.S.C. 811.
• DEA Diversion Control Division, registration and fee information, www.deadiversion.usdoj.gov.

This article is for general informational purposes and is not legal or tax advice. Regulatory requirements change, and operators should verify current requirements with the DEA and qualified counsel before acting.